<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04257006</url>
  </required_header>
  <id_info>
    <org_study_id>1BAX-2020</org_study_id>
    <nct_id>NCT04257006</nct_id>
  </id_info>
  <brief_title>The Effects of Oxiris on Systemic Inflammation and Endothelial dysFunction</brief_title>
  <acronym>EOSIEF</acronym>
  <official_title>The Effects of oXiris on Systemic Inflammation, Endothelial Dysfunction and Volume Control in Cardiac Surgery Patients Undergoing Cardiopulmonary Bypass.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Petersburg State Pavlov Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Petersburg State Pavlov Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CS-AKI occurring in 20% to 70% of cases depending of the type of cardiac surgery. The&#xD;
      systemic inflammatory response is often observed and associated with increased risk of AKI.&#xD;
      Cardiopulmonary bypass (CPB) induces a complex inflammatory response that has a&#xD;
      multifactorial pathogenesis. The inflammatory response is triggered by exposure of the blood&#xD;
      to artificial surfaces during extracorporeal circulation, ischemia/reperfusion injuries,&#xD;
      translocation of gram-negative bacteria from the intestinal tract, small amounts of LPS in IV&#xD;
      solutions. SIRS during CPB with high levels of inflammatory mediators, active complement&#xD;
      proteins and LPS provoke endothelial dysfunction- retraction of endothelial cells with&#xD;
      increasing vascular permeability and thrombogenic activity, also inflammatory mediators&#xD;
      activate leukocytes and they enhance vascular permeability by affecting endothelial cells and&#xD;
      vascular basement membrane. The systemic inflammation and endothelial dysfunction are the&#xD;
      basis for multiple organ dysfunction syndrome. Vascular integrity damage during cardiac&#xD;
      surgery entail redistribution of fluids with interstitial fluid accumulation and require&#xD;
      accurate volume control (pertinent removal of &quot;CPB priming volume&quot;), especially in patients&#xD;
      with CKD (low GFR) with high risks of AKI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific details of Treatment/Intervention: (prescription and/or therapy, devices, equipment,&#xD;
      solutions, product to be used in conducting study:&#xD;
&#xD;
      To apply Prismaflex system with oXiris membrane after cardiopulmonary bypass in SCUF modality&#xD;
      for CPB priming volume elimination.&#xD;
&#xD;
      Duration of procedure: 6 hours Blood flow:150-200 ml/min Anticoagulation: no additional&#xD;
      heparinization.&#xD;
&#xD;
      According to the features of oXiris membrane:&#xD;
&#xD;
        1. Cytokines, complement, endotoxin adsorptive capacity.&#xD;
&#xD;
        2. Capability of accurate fluid balance management after cardiac surgery and CPB.&#xD;
&#xD;
        3. Reduced demand of anticoagulation therapy for CRRT in patients with high risk of&#xD;
           bleeding.&#xD;
&#xD;
      The goal of the research:&#xD;
&#xD;
        1. To evaluate effect of adsorption of oXiris membrane on levels of complement (C3a, C5a),&#xD;
           pro- and anti-inflammatory cytokines (IL-1β, TNF-α,IL-6,Il-8, IL-10,TGF-β), LPS (EAA&#xD;
           levels) after CPB.&#xD;
&#xD;
        2. To evaluate leukocytes activation after CPB and after inflammatory mediators adsorption&#xD;
           with oXiris (CD11b/CD18)&#xD;
&#xD;
        3. To evaluate endothelial dysfunction after CPB and after CRRT with oXiris:&#xD;
           endothelial/leukocytes interactions (ICAM-1, VCAM-1), biomarkers of endothelial&#xD;
           permeability (angiopoetin-2, sFLT-1), biomarkers of endothelial coagulopathy (von&#xD;
           Willebrand factor, thrombomodulin)&#xD;
&#xD;
        4. To evaluate effect of volume control with CRRT on CS-AKI and dependence on mechanical&#xD;
           ventilation after cardiac surgery, regarding volume overload in patients undergoing CPB&#xD;
           with &quot;priming volume&quot; infusion.&#xD;
&#xD;
        5. To evaluate stage and topography of cardiac surgery associated acute kidney injury&#xD;
           (creatinine, cystatin C, NGAL, KIM-1, β2-microglobuline) in patients in two arms: oXiris&#xD;
           and standard protocol.&#xD;
&#xD;
        6. To evaluate adsorptive and volume control feasible effects of oXiris membrane on volume&#xD;
           management (CVP,PAWP), LPS adsorption, reduction of systemic inflammation , endothelium&#xD;
           dysfunction and AKI after cardiac surgery with CPB in comparison with standard protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 17, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient volume status assessment in perioperative period</measure>
    <time_frame>in 24 hours</time_frame>
    <description>To compare volume status in two arms based on CVP mmH2O and PAWP mmHg measurements</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival after cardiac surgery</measure>
    <time_frame>in 90 day</time_frame>
    <description>to compare in arms with oxiris treatment and standard protocol amount of survived patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>'ICU and hospital length of stay after cardiac surgery.</measure>
    <time_frame>in 28 days</time_frame>
    <description>to compare in arms with oxiris treatment and standard protocol the amount of days spent in ICU wards and in hospital</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Kidney Injury Due to Circulatory Failure (Disorder)</condition>
  <arm_group>
    <arm_group_label>patients undergoing CRRT with oXiris membrane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elective cardiac surgery patients undergoing CPB we will range in 2 groups: I- with Prismaflex set oXiris (SCUF) after CPB, II- standard protocol.&#xD;
Indications for CRRT (SCUF) with oXiris after ICU admission:&#xD;
1. Signs of pulmonary edema after cardiac surgery, verified with X-ray control.&#xD;
Or high risk of pulmonary edema after cardiac surgery:&#xD;
Fluid overload ≥ 10%, measured with equation (%fluid overload= ((total fluid in- total fluid out)/admission body weight*100)&#xD;
CVP (central venous pressure) ˃ 12 mm H2O.&#xD;
PAWP (pulmonary arterial wedge pressure) ˃ 12 mm Hg, measured by Swan-Ganz catheter.&#xD;
In this arm the treatment of fluid overload will be provided via SCUF with oxiris membrane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard protocol</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Elective cardiac surgery patients undergoing CPB we will range in 2 groups: I- with Prismaflex set oXiris (SCUF) after CPB, II- standard protocol.&#xD;
Indications for CRRT (SCUF) with oXiris after ICU admission:&#xD;
1. Signs of pulmonary edema after cardiac surgery, verified with X-ray control.&#xD;
Or high risk of pulmonary edema after cardiac surgery:&#xD;
Fluid overload ≥ 10%, measured with equation (%fluid overload= ((total fluid in- total fluid out)/admission body weight*100)&#xD;
CVP (central venous pressure) ˃ 12 mm H2O.&#xD;
PAWP (pulmonary arterial wedge pressure) ˃ 12 mm Hg, measured by Swan-Ganz catheter.&#xD;
In this arm the management of fluid overload will be provided via diuretics or IHD (in condition diuretics treatment resistance)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>oXiris membrane</intervention_name>
    <description>Open heart surgery patients in early postoperative period with clinical signs of fluid overload undergoing CRRT</description>
    <arm_group_label>patients undergoing CRRT with oXiris membrane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  elective cardiac surgery patients undergoing CPB (&gt;60 minutes) with valve replacement&#xD;
             and CABG.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Immunosuppressive therapy, CKD 4 and 5 stages, RRT in last 90 days, pregnancy,&#xD;
             autoimmune disease, allergy to heparin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yury Polushin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pavlov First St. Petersburg State Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yury Polushin, PhD</last_name>
    <phone>+7 (812) 338-66-49</phone>
    <email>polushin1@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dmitry Sokolov, MD</last_name>
    <phone>+7(911)7193333</phone>
    <email>sokolovdv82@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pavlov First St. Petersburg State Medical University</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Russsia</state>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yury Polushin, PhD</last_name>
      <phone>+78123387823</phone>
      <email>polushin1@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Dmitry Sokolov, MD</last_name>
      <phone>+79117193333</phone>
      <email>sokolovdv82@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 17, 2020</study_first_submitted>
  <study_first_submitted_qc>February 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute kidney injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>de-identified individual participant data for all primary and secondary outcome measures will be made available</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>data will be available within 1 year of study completion</ipd_time_frame>
    <ipd_access_criteria>data access request will be reviewed by an external independent review panel.</ipd_access_criteria>
    <ipd_url>http://1spbgmu.ru</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

